Elective nodal radiotherapy with a gapless radiation field junction for oligorecurrent prostate cancer after previous radiotherapy

被引:0
|
作者
Li, Minglun [1 ]
Fan, Yourong [1 ]
Trapp, Christian [1 ]
Schmidt-Hegemann, Nina Sophie [1 ]
Ma, Jing [1 ]
Buchner, Alexander [1 ]
Lu, Shun [1 ]
Xu, Bin [1 ]
Stief, Christian [1 ]
Wang, Xuanbin [1 ]
Zhou, Cheng [1 ]
Belka, Claus [1 ]
Rogowski, Paul [1 ]
机构
[1] Ludwig Maximilians Univ LMU, Univ Hosp Munich, Munich, Germany
关键词
ENRT; Nodal oligorecurrence; Gapless radiation field junction; Reirradiation; PSMA-PET; CT; RADICAL PROSTATECTOMY; SALVAGE RADIOTHERAPY; THERAPY; TOXICITY; PATTERNS; REIRRADIATION; RECURRENCE; FAILURE;
D O I
10.1016/j.ctro.2022.100571
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To evaluate the feasibility of subsequent elective nodal radiotherapy (ENRT) for nodal recurrences after previous radiotherapy with a defined planning approach for a gapless radiation field junction.Methods: Patients with 1) previous radiotherapy of prostate or prostatic fossa and subsequent pelvic ENRT or 2) previous pelvic radiotherapy and subsequent ENRT to paraaortic lymph nodes (LN) and gapless junction of both radiation fields were analyzed. The cumulative maximum dose (Dmax-cum) and the maximum cumulative dose in 1 cc (D1cc-cum) were estimated. Absolute toxicity and the toxicity exceeding baseline were evaluated.Results: Twenty-two patients with PSMA-PET/CT-staged nodal oligorecurrence after prior radiotherapy were treated with pelvic (14 patients) or paraaortic ENRT (9 patients). One patient was treated sequentially at both locations. Median time between first and second RT was 20.2 months. Median doses to the lymphatic pathways and to PET-positive LN were 47.5 Gy and 64.8 Gy, respectively. The planning constraint of an estimated Dmax-cum < 95 Gy and of D1cc-cum < 90 Gy were achieved in 23/23 cases and 22/23 cases, respectively. Median follow-up was 33.5 months. There was no additional acute or late toxicity >= grade 3. Worst acute toxicity exceeding baseline was grade 1 in 68.2% and grade 2 in 22.7% of patients. Worst late toxicity exceeding baseline was grade 1 in 31.8% and grade 2 in 18.2% of patients.Conclusion: ENRT for nodal recurrences after a previous radiotherapy with gapless junction of radiation fields seems to be feasible, applying the dose constraints Dmax-cum < 95 Gy and D1cc-cum < 90 Gy without grade 3 acute or late toxicities exceeding baseline.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] PSMA-PET-based Radiotherapy of Oligorecurrent Lymph Node Recurrence in Prostate Cancer after radical Prostatectomy and Salvage Radiotherapy
    Henkenberens, C.
    Oehus, A. -K
    Soldatov, A.
    Schmidt-Hegemann, N-S
    Vogel, M.
    Kirste, S.
    Belka, C.
    Combs, S. E.
    Grosu, A. -L
    Becker, J.
    Mueller, A. -C
    Kroeze, S. G. C.
    Guckenberger, M.
    Christiansen, H.
    Walacides, D.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2019, 195 : S152 - S153
  • [22] Oligorecurrent nodal prostate cancer: Radiotherapy quality assurance of the randomized PEACE V-STORM phase II trial
    Achard, Verane
    Jaccard, Maud
    Vanhoutte, Frederik
    Siva, Shankar
    Heikkila, Reino
    Dirix, Piet
    Liefhooghe, Nick
    Otte, Francois-Xavier
    Gomez-Iturriaga, Alfonso
    Berghen, Charlien
    Shelan, Mohamed
    Conde-Moreno, Antonio
    Campos, Fernando Lopez
    Papachristofilou, Alexandros
    Guckenberger, Matthias
    Meersschout, Sabine
    Putora, Paul Martin
    Zwahlen, Daniel
    Counago, Felipe
    Scorsetti, Marta
    Eito, Clara
    Barrado, Marta
    Zapatero, Almudena
    Muto, Paolo
    Van De Voorde, Lien
    Lamanna, Giorgio
    Koutsouvelis, Nikolaos
    Dipasquale, Giovanna
    Ost, Piet
    Zilli, Thomas
    RADIOTHERAPY AND ONCOLOGY, 2022, 172 : 1 - 9
  • [23] The role of whole pelvic nodal radiotherapy compared with prostate bed only radiotherapy after radical prostatectomy for prostate cancer.
    Caubet, Matthieu
    Pasquier, David
    Bertaut, Aurelie
    Grobois, Simon
    De Bari, Berardino
    Kleinclauss, Francois
    Vuillemin, Antoine Thiery
    Martin, Etienne
    Quivrin, Magali
    Cormier, Luc
    Crehange, Gilles
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [24] Clinical outcome of PSMA-guided radiotherapy for patients with oligorecurrent prostate cancer
    Koerber, Stefan A.
    Sprute, Katharina
    Kratochwil, Clemens
    Winter, Erik
    Haefner, Matthias F.
    Katayama, Sonja
    Schlampp, Ingmar
    Herfarth, Klaus
    Kopka, Klaus
    Afshar-Oromieh, Ali
    Zschaebitz, Stefanie
    Holland-Letz, Tim
    Choyke, Peter L.
    Jaeger, Dirk
    Hohenfellner, Markus
    Haberkorn, Uwe
    Debus, Juergen
    Giesell, Frederik L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (01) : 143 - 151
  • [25] Radiotherapy with or without antihormonal therapy for PSMA-positive oligorecurrent prostate cancer
    Kroeze, S.
    Henkenberens, C.
    Schmidt-Hegemann, N.
    Vogel, M.
    Kirste, S.
    Becker, J.
    Christiansen, H.
    Belka, C.
    Combs, S.
    Grosu, A.
    Mueller, A.
    Guckenberger, M.
    RADIOTHERAPY AND ONCOLOGY, 2019, 133 : S822 - S823
  • [26] Feasibility of permanent implants for prostate cancer after previous radiotherapy in the true pelvis
    Battermann, JJ
    RADIOTHERAPY AND ONCOLOGY, 2000, 57 (03) : 297 - 300
  • [27] Clinical Outcome of PSMA-Guided Radiotherapy for Patients with Oligorecurrent Prostate Cancer
    Sprute, Katharina
    Koerber, Stefan A.
    Kratochwil, Clemens
    Haefner, Matthias F.
    Rathke, Henrik
    Herfarth, Klaus
    Kopka, Klaus
    Holland-Letz, Tim
    Haberkorn, Uwe
    Debus, Juergen
    Giesel, Frederik L.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 73 - 73
  • [28] Stereotactic radiotherapy for limited nodal prostate cancer disease
    Grespi, S.
    Casamassima, F.
    Menichelli, C.
    Fanelli, A.
    Tubin, S.
    Pastore, G.
    Arrichiello, C.
    Ferullo, A.
    RADIOTHERAPY AND ONCOLOGY, 2015, 115 : S368 - S368
  • [29] Stereotactic radiotherapy for isolated nodal recurrence of prostate cancer
    Detti, B.
    Bonomo, P.
    Masi, L.
    Doro, R.
    Cipressi, S.
    Iermano, C.
    Bonucci, I.
    Franceschini, D.
    Di Brina, L.
    Bakhi, M.
    Simontacchi, G.
    Meattini, I.
    Livi, L.
    WORLD JOURNAL OF UROLOGY, 2015, 33 (08) : 1197 - 1203
  • [30] Stereotactic radiotherapy for isolated nodal recurrence of prostate cancer
    B. Detti
    P. Bonomo
    L. Masi
    R. Doro
    S. Cipressi
    C. Iermano
    I. Bonucci
    D. Franceschini
    L. Di Brina
    M. Bakhi
    G. Simontacchi
    I. Meattini
    L. Livi
    World Journal of Urology, 2015, 33 : 1197 - 1203